Thurman Wheeler

Adding a cell-penetrating peptide to a compound that reduces clump formation in cell nuclei increased its effectiveness in type 1 myotonic dystrophy research mice

posted on February 27, 2013 - 3:51pm
Scientists at the biopharmaceutical company Genzyme, working with mice, say they have modified and improved an existing experimental strategy to treat type 1 myotonic muscular dystrophy (MMD1, also known as DM1).

New content is being added every day. Please check back again.